Vaxcyte Finalizes $600.2M Public Offering with Full Over-Allotment Exercise
Summary
Vaxcyte, Inc. announced the finalization of its public offering, including the full exercise of the underwriters' option, resulting in total net proceeds of approximately $600.2 million.
Key Events
-
Offering Finalized and Closed
Vaxcyte, Inc. completed its public offering on February 2, 2026, selling 11,000,000 shares of common stock at $50.00 per share.
-
Over-Allotment Option Fully Exercised
Underwriters notified Vaxcyte on January 30, 2026, of their intent to fully exercise their option to purchase an additional 1,650,000 shares.
-
Significant Capital Infusion
The total offering, including the over-allotment, generated approximately $600.2 million in net proceeds for the company, substantially strengthening its financial position.
Analysis
This 8-K filing provides the definitive details of Vaxcyte's public offering, confirming the full exercise of the underwriters' over-allotment option. This brings the total capital raised to approximately $600.2 million, a substantial increase from the initial offering size. The successful completion of this significant financing event, including the strong demand evidenced by the full option exercise, provides Vaxcyte with considerable funding to advance its clinical-stage vaccine pipeline and operations. This filing follows the preliminary prospectus on January 29, 2026, and the initial finalization reported on January 30, 2026, adding the crucial detail of the over-allotment exercise.
At the time of this filing, PCVX was trading at $57.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5B. The 52-week trading range was $27.66 to $91.86. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.